These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 3305463)

  • 1. Effect of a diazaborine derivative (Sa 84.474) on the virulence of Escherichia coli.
    Lam C; Turnowsky F; Högenauer G; Schütze E
    J Antimicrob Chemother; 1987 Jul; 20(1):37-45. PubMed ID: 3305463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A diazaborine derivative inhibits lipopolysaccharide biosynthesis.
    Högenauer G; Woisetschläger M
    Nature; 1981 Oct; 293(5834):662-4. PubMed ID: 7027050
    [No Abstract]   [Full Text] [Related]  

  • 3. Cell wall composition and virulence in Escherichia coli.
    Medearis DN; Camitta BM; Heath EC
    J Exp Med; 1968 Sep; 128(3):399-414. PubMed ID: 4875325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of lipopolysaccharides in the action of the bactericidal/permeability-increasing neutrophil protein on the bacterial envelope.
    Weiss J; Muello K; Victor M; Elsbach P
    J Immunol; 1984 Jun; 132(6):3109-15. PubMed ID: 6373924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the wzy gene in lipopolysaccharide biosynthesis and pathogenesis of avian pathogenic Escherichia coli.
    Zuo J; Tu C; Wang Y; Qi K; Hu J; Wang Z; Mi R; Yan Huang ; Chen Z; Han X
    Microb Pathog; 2019 Feb; 127():296-303. PubMed ID: 30553014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum resistance and virulence of Escherichia coli isolated from turkeys.
    Ellis MG; Arp LH; Lamont SJ
    Am J Vet Res; 1988 Dec; 49(12):2034-7. PubMed ID: 3071193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [wzzE does not affect lipopolysaccharide phenotype of avian pathogenic Escherichia coli from clinical ducking].
    Zuo J; Han Y; Zhang Y; Yang L; Xu D; Wang S; Qi K; Han X; Yu S
    Wei Sheng Wu Xue Bao; 2016 May; 56(5):891-9. PubMed ID: 29727150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen.
    Noursadeghi M; Bickerstaff MC; Gallimore JR; Herbert J; Cohen J; Pepys MB
    Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14584-9. PubMed ID: 11121061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of lipopolysaccharide biosynthesis impair the virulence potential of Escherichia coli.
    Hammond SM
    FEMS Microbiol Lett; 1992 Dec; 100(1-3):293-7. PubMed ID: 1335947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of a lipopolysaccharide-initiated, cytokine-mediated host defense mechanism in mice against extraintestinally invasive Escherichia coli.
    Cross A; Asher L; Seguin M; Yuan L; Kelly N; Hammack C; Sadoff J; Gemski P
    J Clin Invest; 1995 Aug; 96(2):676-86. PubMed ID: 7635960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virulence-associated acquisition of iron in mammalian serum by Escherichia coli.
    Kochan I; Kvach JT; Wiles TI
    J Infect Dis; 1977 Apr; 135(4):623-32. PubMed ID: 140199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro studies on the interaction between mouse peritoneal macrophages and strains of Salmonella and Escherichia coli.
    JENKIN C; BENACERRAF B
    J Exp Med; 1960 Aug; 112(2):403-17. PubMed ID: 13789820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virulence factors of Escherichia coli. IV. Association in Escherichia coli of LD50 with haemolysin production, haemagglutinating capacity, antigens K1, K5 colicinogenicity and pathogenicity.
    Czirók E; Milch H; Vincze I
    Acta Microbiol Hung; 1987; 34(1):25-37. PubMed ID: 3307277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes.
    Horwitz MA; Silverstein SC
    J Clin Invest; 1980 Jan; 65(1):82-94. PubMed ID: 6985617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the opsonic capacity of core lipopolysaccharide antiserum of equine origin against smooth Escherichia coli 0111:B4, using macrophage chemiluminescence.
    Morris DD; Harmon BG; Moore JN
    Am J Vet Res; 1989 Aug; 50(8):1272-8. PubMed ID: 2675693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human IgG but not IgM antibodies can protect mice from the challenge with live O6 Escherichia coli.
    Pontes GN; Massironi SG; Arslanian C; Palmeira P; Carneiro-Sampaio MM; Nagao AT
    Scand J Immunol; 2005 Oct; 62(4):353-60. PubMed ID: 16253122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance of gram-negative bacteria to purified bactericidal leukocyte proteins: relation to binding and bacterial lipopolysaccharide structure.
    Weiss J; Beckerdite-Quagliata S; Elsbach P
    J Clin Invest; 1980 Mar; 65(3):619-28. PubMed ID: 6986410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunochemical specificity of human antibodies to lipopolysaccharide from the J5 rough mutant of Escherichia coli O111:B4.
    Schwartzer TA; Alcid DV; Numsuwan V; Gocke DJ
    J Infect Dis; 1989 Jan; 159(1):35-42. PubMed ID: 2462603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticore endotoxin F(ab')2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis.
    Dunn DL; Mach PA; Condie RM; Cerra FB
    Surgery; 1984 Aug; 96(2):440-6. PubMed ID: 6379963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine production induced by non-encapsulated and encapsulated Porphyromonas gingivalis strains.
    Kunnen A; Dekker DC; van Pampus MG; Harmsen HJ; Aarnoudse JG; Abbas F; Faas MM
    Arch Oral Biol; 2012 Nov; 57(11):1558-66. PubMed ID: 22902095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.